# Allovir

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allovir

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.allovir.com
- Total disclosed funding: $121M
- Latest round: Series B (May 8, 2019)
- Investors on record: 8

## About

Allovir, Inc. is a biotechnology firm focused on developing innovative therapies to treat viral infections in immunocompromised patients, leveraging advanced cellular technology for effective solutions.Founded in 2013 and headquartered in Cambridge, US, Allovir, Inc. develops therapies for viral infections. The company has successfully raised a total of USD 276.25 mn through three funding deals, the latest being an IPO on July 29, 2020, which raised USD 276.25 mn. Key founders include Ann Leen and Haifa Hamdi, and the current CEO is Diana Brainard.Allovir, Inc. specializes in innovative treatments targeting viral infections, particularly those affecting immunocompromised patients. Their primary products leverage proprietary cellular technology aimed at improving patient outcomes. These therapies are designed for healthcare providers administering treatments to vulnerable populations, primarily within the US market, with plans to expand internationally.In their most recent financial year, Allovir, Inc. reported revenues of USD 0, with an EBITDA of -USD 65.44 mn, highlighting the early-stage nature of their commercialization efforts as they work towards bringing their therapies to market.Allovir, Inc. plans to use the proceeds from their July 2020 IPO, which raised USD 276.25 mn, to support the development and marketing of their therapies. The company is focusing on expanding its product offerings and entering new markets. Specific expansion targets and launch dates for upcoming products are part of their strategic roadmap as they seek to broaden their reach beyond the US.

## Funding rounds

- Series B, May 8, 2019, $121M — Invus [DUP], Fidelity Investments, Gilead Sciences, Inc., Leerink Partners, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital

## Investors

- Invus [DUP] — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Gilead Sciences, Inc. — Series B
- Leerink Partners — Series B
- F2 Ventures (https://capitalatlas.ai/funds/f2-ventures) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B